XERS - Earnings call transcript Q3 2024 | Xeris Biopharma Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, and welcome to the Xeris Biopharma Third Quarter 2024 Financial Results Conference Call. My name is Harry, and I'll be your operator today. [Operator Instructions]

I would now like to hand the conference over to Allison Wey, Senior Vice President of Investor Relations and Corporate Communications. Thank you. ahead. go Please

Allison Wey

we and our third Harry, questions. John We you we can the This appreciate our our open release Thank results, will After detailed results good our call our which morning, CFO. Pieper, quarter and found by for a today. joining press CEO; with on you, be Steve morning. issued website. I'm line Shannon, remarks, joined prepared

contain forward-looking we performance. that will Before I this expectations, future to would financial concerning you remind statements plans, begin, like and company's the call prospects

statements uncertainties materially actual Forward-looking are could subject forward-looking those and to differ that to risks results statements. cause from

forward-looking information risk subject call obligations statements. represent statements earnings such on of to refer please our release views more only such factors to date and our and in disclaim call as of this our We any update Any in For included the to this risks, filings. law. applicable SEC

to Let me now pass over the John. call

John Shannon

good morning, of nearly and revenue strong million revenue product Allison, quarter Gvoke. proud and and of million over Thanks, led total Recorlev record-breaking another everyone. demand $XX by with and report $XX to excited of I'm

respectively. That's XXth a with Our of growth XX% XX% marks X quarters quarters row last the and XX quarter product XX%, of XX% over the growth. now of over revenue growth right, in consecutive XX% to accelerating

see them all is Xeris team on focused on proud driving executing entire to I'm The and growth, fronts. so

technology advanced lead once-weekly levothyroxine, planned subcu In of on as addition commercial our partner XP-XXXX, to pipeline and product, also programs. outstanding we our our our success, executed significantly all

outlined CEO. in three primary focus August, strategic months, when several priorities been has last became our executing the I the back I Over

rapid strategic transparency ensuring our are: maintain our a stakeholders. sheet balance reminder, first, and you, growth while enhancing our second, strong third, growth with and a communications of As to we and our financial investments; discipline enhancing priorities sustained these our franchises; fund commercial the

accelerating starting brand. doing, rapid pleased product of to and with record the the continuing XX% product we're report another how this execute of in the get durability three of quarter Gvoke revenue to quarter the I'm ongoing priority let's So a products, growth one. Recorlev, our our team by hallmarked growth last to resulting growth plans, of year. in compared commercial continued QX Across all Keveyis sales,

Recorlev's Looking each we saw with specifically new products. record in line a number best-in-class at In third the our of referrals quarter. of profile,

XXX% efficient compared team has the year. to the which In has and most on support Recorlev, ensuring driven smoothest increase addition, a on been new process in patient getting started focused starts last patients to

Our with Cushing's result $XX targeted Recorlev gland. whom QX have, the to Cushing's and by is our of over curative. accelerating syndrome caused last the nearly been a 'XX commercial up million, of patients not revenue often option chronic Endogenous hypocortisolemia pituitary surgery syndrome cortisol exposure, an for elevated tumor endogenous not profile orogerenal or a best-in-class hypercortisolemia up benign of view, has is continues for are investments Recorlev and in XX% growth the quarter. Recorlev XXX% over to on

tablet been This is cortisol has and oral shown where safely an normalize etiologies. across Recorlev twice-daily levels comes multiple effectively in, that to

this increased that Recorlev we to momentum. size build patient priority, the of future. to fuel our Every And Cushing's in the creating on in expect and marketplace and rapidly of recall, for people is sales teams in tailwinds focused ultimately being strong we and investment syndrome tested the mentioned disciplined I diagnosed continuing expanding and XX% And by as screened, support Recorlev. more hypercortisolemia. part As August, and more are day, just expansion strong July our growth with

hypoglycemia. who now given market the people diabetes population for overall potential, are with enormous to have of severe to This Gvoke. Turning at product continues risk

increase as to continuing an in pleased well We of third prescriptions new revenue, prescribers prescribers. increasing to a number very a XX% increase quarter, $XX as XX% repeat from in efforts almost increase. total see are saw million In pay Gvoke We in off. achieved the coming our an

auto-injector share to Excitingly, have all XX%. glucagon ready-to-use can for carry standing with our new requires and times. continue a at steadily with to at is best we Gvoke a gain reliable prescription now treatment way The prompt medical market can and/or be prime is hypoglycemia swiftly that to of easy-to-use, share symptoms. treatment at use and the a glucagon to glucagon prescription emergency that product patients an life-threatening Severe ensure onset intervention. filled

surface just very million scratching a long XXXX, people with patient still patent And unprotected. XX total population to addressable the Gvoke has runway. of the are We of over protection

up durability is Keveyis the a branded commercial execution Wrapping of as product. the

we a care thrilled by to strong community of Keveyis are dedication system generated health that the support to patient to We that valued the translating continued both is the in believe have best-in-class, is the see Keveyis tremendous competition, and and for provider. such surrounded by and brand. Despite availability medical generic support the patient to

in fact, support every patients continue fourth still week. early we PPP while the quarter, new In we're and to find

guidance exceptional expectations performance $XXX million. to to and $XXX year, year-to-date excited for our announce we raising the the are Given our million of remainder I'm revenue to

long-term enables priority, and bit. a short- investments, detailed our which our second execution the Moving in of will Steve to renewed discipline strategic commitment of just strategic go financial and value. financial creation growth through results to our

highlights. just I'll few cover a So key

with great strides made We've profile. financial our

million of revenue us allows cash XX% our margin over with in conduct greater very in remain growth, that disciplined led and franchises anticipate $XX Our the with need fast-growing our expense profile invest business value the to XP-XXXX. the contributing financing. growth This our We are to product any management commercial cash. all healthy strong our by will along in no than our of pipeline, position dilutive stage our driver, development core advancements to

hypothyroidism particular, from research, the data our the in that in hand, III referred the perform the of excited because market, II the were meeting, get out more therapy. oral range. out initiated I American being can't discussions and patients Thyroid XP-XXXX. positive Phase to Association program owing control the who market the more Phase the in we with the stress patients they at Phase of control their to size screened we this data were evaluate and With presented of a Last number of with showing clinical study in normal are week, registrational we XX% enough, as study FDA of unable study, data II the we for hypothyroidism clinical with preparation overall to

with plans and timelines. look we work finalizing engagement favorable had further the have through as We and forward agency interactions to

optimal While to the a in we and provide we to of determine expect fulsome half update assess registration, XXXX. to path be first the able

partner of our each agreement, programs. progressing and They are mention partnership Just all actively working we're per partnerships. a brief new on technology potential

XeriSol the potential unique Our technologies features of may our our partners businesses. and and XeriJect respective recognize the provide platforms benefits their to current and

As our partnership our will programs meaningful advance updates. results, sure to more provide and to contributors business be become we

and this growth to Moving with the with that transparency community, improving been all happy very of of current hear your digging been increasing personally from much many busy our recognize communications. I to priority. as delivering our assets. the you and We've intention have executing was of strategic I getting the meaningful with our third our investor into we connecting quality and enjoy hearing feedback. that can investors role share CEO I and

of We the part to you a greater company, metrics to as also of our clarity even understand us would and our provide committed more that health clear guidance. share providing like would of picture long-term we're XXXX

you the in significant Xeris we see long the execution most short and value of fast-growing company as pipeline products heard create to well thing and all and positioned term. unique a Finally, exciting that almost with a multiple shareholder promising consistent was

it that, Steve financial hand I'm review results and for to over quarter With our going to year-to-date. the to

Steven Pieper

and good Thanks, morning, everyone. John,

and very pleased we highlighted positive our momentum As our with with the results John are earlier, third seeing business. are quarter we

We greater the million, Remember million, prespecified product to and respectively, was revenue quarter, than for revenue in the to million third increasing On million ended by approximately total and and million basis, revenue respectively Horizon. growth. product year-to-date milestone approximately marks XX% profile net increasing year. year. year, $X $XX.X XX%, target was revenue with This revenue XX% XXth QX consecutive compared $XX.X prior product product compared achieving net quarter with the $XXX last of XX%, recognized by $XXX.X total that a prior we and XX% of from

Excluding for and that year. XX% nonrecurring and by increased versus item, total year-to-date prior the XX% revenue quarter

products. our to Moving

we acceleration the from by excited are seeing Recorlev. are We

a $X million, to net Recorlev revenue doubling was year periods. million quarter, compared compared year prior net $XX.X revenue both sequential more the increased was the QX. basis, Recorlev million and over for to For than On by $XX.X

growing them result more $X.X by million and quarter-over-quarter For net first of pipeline quarter, reference, This a to increased into on our quarter. is acceleration Recorlev ability our revenue last to convert compared Recorlev. the referrals patients of

We see completed increase continue we versus that the growing commercial an new in XX% recently continue. QX. Recorlev patients with momentum expect this And will to expansion

primarily million was prior growth representing an increase in period. XX% Consistent Gvoke $XX.X for a and Gvoke back-to-school years, by in quarter and to the was total healthy $XX.X a last Gvoke on This net periods driven the increase year. basis, compared maintained with revenue the million growth XX% year-to-date same prescriptions.

the has increased weekly most as market as in are share continued We XX% Gvoke's growth confident new prescription of over recent data. to

to year-to-date and $XX.X million for we quarter row $XX.X patients increase Keveyis number saw Keveyis in quarter on net for and we of of a continue respectively. QX, was modest strong In second referrals. the revenue in pipeline the million, a as a generate the

to in competitive decreased, against extremely pricing. of today, net impact modest has Keveyis generic pharmacy result ability confident in continue a negative competition. Keveyis remain here our we to As to a pressure, generic reimbursement Sitting defend resulting

of are guidance $XXX are $XXX the revenue million the of from total performance previous of all $XXX to guidance momentum our to $XXX the strong products raising million. and generating, Given million million we our to three we

of XX.X% cost a goods Moving of a goods CMOs are percent changes and to to of our with we the increase increased supply basis. meet QX many capacity revenue for are our and sold. biopharmaceutical companies, process on to maintain product we and growing on strategically able ensure in fast-growing to adequate XX.X% to sold products. an total Like year-to-date Cost implementing demand as

to is as quarter. support process efforts. to wrote capacity required manufacturing we off cash noting ongoing impact expansion of a had charge It no of components quarter, that in worth changes $X.X this result Gvoke This the million

and focused to products, support accordingly. We adequate we invest supply our ensuring on are fast-growing we'll continue to have

notably Research partnerships. and technology primarily for to development primarily third support our comprised basis, increase year-to-date continued costs pipeline investment the quarter, costs of compared XXXX expenses our of and were were a continued and $X.X the and pipeline, prior expenses technology increased platforms which relatively to quarter third partnerships. flat research investment personnel On our million compared million the our XP-XXXX, and development $X.X for in were a platforms to was for and million, year, $XX.X in

million Selling, $X.X administrative $XXX.X previously were million general to year. plan for driven primarily expenses respectively, and These $XX resulting announced XX% to corporate in and costs of CEO year-to-date, third and and in compared the and by increases XX% were increase a restructuring, succession one-time an prior of quarter. million the the related quarter related charge

Recorlev Excluding increase increased compared was of by of our the This this driven SG&A commercial charge, nonrecurring by last QX only to X% expansion year. organization.

succession the to CEO in $X.X plan when the to charges these approximately we non-routine product total as able perspective, related quarter, of generating were as growth write-off. prior you versus quarter. XX% quarter restructuring operating million, expenses component relatively We expense the operating charges revenue while ended last a and keep relatively includes which flat exclude the Gvoke well flat From

in this to We utilization strong with quarter QX. to ended every into a year, cash over and expect million. improved continue that cash. Moving quarter $XX we the Cash position has trend

which the to million revenue to business, $XX in $XX our XXXX well considers $XX million. associated increased commercial health our million cash to tightening are expansion, we as expenses guidance confidence as Given million guidance QX of $XX the Recorlev with our from ending the our

our maintain is business manage strong financially dilutive gives will that to the profile financing fund expenses, to not require and any robust diligently and us confidence drive does margin We growth, continue sound our revenue which growth.

provide questions. lines open detailed we will Looking year-end our to for please in we XXXX, March. With operator, when release results guidance the that, financial ahead

Operator

Knickerbocker [Operator Chase question be the today Craig-Hallum. with Instructions] first of Our will line from

Chase Knickerbocker

here of you a us here. as kind for the what that the see within from seemingly, first, about really growth on quarter attractive continues. entering market you kind drivers Recorlev think business, obviously, great and curtain QX. and a John, what bit of maybe on here. this of market just, for a growth as see about really your kind kind help us sort of a talk Congrats of specifically, inflection think of specific pipeline and kind this I bit peel has kind back Because little your investors execution think team's the And little of can specific profile

Just kind there. level of speak to your confidence

John Shannon

Yes.

really riding Recorlev and if I kind this market on that that product want think is terms a you really of a And we're great growth. tailwinds think production, and normalize cortisol I is in about cortisol product as of the to right, inhibit maintain that. with

are identifying helping started. on Cushing's expansion our out people team of well And really our respect. success who hypercortisolemia get market really that have as people driven that access who So by them in we're riding them there as is people our patient these with

about, my with as and and getting in those starts. the hear we're and script pulling lot patient filling the we're you as better referrals, better referrals we've into top new a of talked So at pipeline

X driven our So our team XXX% are and support those by out the aspects field. in services

Chase Knickerbocker

Great. And then maybe...

John Shannon

the about I the should. pipeline -- Talk yes, yes, in

So to with the on both. we're accelerating respect pipeline

And top at accelerating top the like at We're -- referrals. or of the of funnel that call accelerate level. we been like is driving we've what the it pipeline we to ends. both So continue to that those

great. looking it's So

Chase Knickerbocker

maybe breakeven. us a path about Great. help kind to And of Steve, little then bit think the

kind balance as as about a flow sustainably. the of guys levo guided kind of on 'XX, Phase should walk of in implied are kind essentially kind And guidance. cash us kind within think inflection III QX You through to margins, of that potential how go-forward getting program and cash continued we into you in cash to a positive breakeven go then business of investors basis breakeven showing your position flow we

Steven Pieper

I and guide for question, asking thanks me the Chase, you on to Yes. appreciate 'XX.

provide my we're in not prepared mentioned prepared remarks, 'XX I yet. As to guidance that

Specifically there, discussions FDA done with underway. levo, there's be still work to

provide the thinking to a our how we of So half update and 'XX expect first 'XX. into in more that factors fulsome for

hit strong remarks, you operating in prepared one-time coupled the And the I something back my we're think out on business, in with yes, trajectory a I couple top margin the on our when mentioned were the expenses But profile. you quarter. charges line, that, really in of particularly relatively confident flat a of that

But in here more the we of sitting about see feeling profile March Xeris and very think So we'll we're path I and that of financial confident provide detailed guidance year. heading. next we're where

Operator

of next with The question Gershell Oppenheimer. Leland will be from the line

Leland Gershell

Great execution on here. another quarter

P&L, after earlier lesser $X.X the the Just this write-off, Gvoke like looks been a the back have margin the it been Steve, little question cost may than of out had the you gross bit a from on year. goods, million

the think wondering about going comment Just we can if should through and you maybe that fourth forward? how quarter

Steven Pieper

write-off company size time. you I a with Gvoke, time of has biopharmaceutical that quarter. write-offs gross in Yes. that And margin. don't anticipate typically same fourth specifically assume as margin. fair gross Recorlev, think degree continue it's look, overall in look, on our sell I I the higher, chain, We I as would just the bit have probably particularly a of little supply we think, from write-off but with don't the the to quarter say But the to that -- it the think improve was third should was product-level we -- to more comment

gross we balance, margins to should north So it in that of spot. look on remain as continue we and at healthy XX%,

Leland Gershell

broad of this for XXXX just pivotal could for if continue into Got know get discussions on strokes year. and share may we you at be it. just next as early be you XXXX. I And see with clarity what point, we'll clinical this wondering would you trial John, But that into FDA coming

John Shannon

into in in terms not things a I'm we're terms that in product it's discussions prepared Yes, and we an like to label, with what of to want that. you want get kind things because, I in accomplish process like said, this of of iterative

to want give that right of now. stuff don't on opinion I any So an

Operator

the will H.C. Livnat next today The line question of from with be Oren Wainright..

Oren Livnat

about parts On and just average price a that a net slightly follow-up. with increase the of yet just sequential versus July, total payer were in pull-through growth growth moving year-over-year. growth? impressive to the I of lower the know -- patient there year-over-year maybe was year-over-year. pulls more pushes curious within Recorlev, dose you just you Are terms talk to net. gross some I'm there the if Can have And really I and that's sales in than timing of just dynamics. lumpiness or regards

John Shannon

funnel were still dynamics. like What's you And like parameters things driving all now that not enough. right the pulling persistence at things other things really and that's really dose, of we're payer emphasize and It's having them I like And is right patient asking patients now. same. top new growth is that through Recorlev about and new can't the the game similar adding starts. we're are That's and success. great the to -- where

going of things start going time to slow new quickly, you're to come go of things Over And those time, fine. like patients are But that's so when move. dosing terms to some raising up, are in other and low take and and physicians that things up. Oren, adding

Our get them them get and -- get get on them now started. to patients goal the right started referred and is

Oren Livnat

sorry. about makeup Talk go the between -- ahead,

John Shannon

not pressure just a having we're No, payer stuff.

it be must just of So timing where patients...

Oren Livnat

in being the patient overall an in give is think over, switch may both of the possible is you've which off-label first-line for for portion pretty talked reason uncontrolled what is the think And patients about you of the I some that of latter, update the larger Cushing's excited just do a is and even between makeup already. switchers? you this market, on it patients patients I versus just but that And more us given first-line even patients, and the about now approved therapy a seeing past, overall Okay. keto? Can would base controlled switch, maybe guess likely, main

John Shannon

mix, So patients I the new it's and have lot but draw a of we're -- switches. of exact we to a don't naive lot get getting

the amongst cortisol switching significant -- especially and Recorlev reason percentages them of -- if the Recorlev's there. the don't physicians both to to it's they So and production, -- is them. want normalize choice patients, the not so in cortisol. normalize else, again, it's I we're on inhibit getting and again if know and but really on exactly, usually choice. And best If they're something is the great these cortisol they're switches, want to control new

Oren Livnat

digits including on you've that generics, insulin talked prescribed out seeing this the to about All for get more overall or given therapy? glucagon get think it's well, how probably the it start it underpenetration new it's for market, huge more will right. this And of nauseum -- existing now, an ad Gvoke, to I'm guidelines The so take? long like overall clearly, population, with standard And of take accelerate, is ad but in in what now. you nauseum, low at-risk applications probably, doesn't the starting new do care, these wondering, market right, old the we yet not why it single just not And point EpiPen market rescue. patients will to but ones look at-risk to rescue

John Shannon

Yes.

we're be do drive should It and standard is the doing of only with trying based the make honest. clinicians, to practice care. the it, We're trying to It ones the you So started. of on just me it should we're standard that. care be to for the be let of guidelines. where What start standard

care any it game the the practice offices, we're it's make of them marketplace driven physicians' of standard there That's of for. going by alerting of change and getting this by growth being Xeris and team their so to part standard them And -- in out practice. is into the

out But is lot a how pop? And for get have is going run out I fights there you on we'll to we're it long do protected until can long for Gvoke it take? done. tell we an every make And and And and I that is ones work to sure aren't and the of what you. to it going the that. runway continue this day When to we to runway. team to of are have a don't really answer time the going gets protected, patients

exactly fight. know don't I in long, the So how we're but for

Oren Livnat

right. All

breakout, some OpEx quick maybe give like one Is It one. little to likely a detail next your hope and going guidance in in Just well? margin year visibility TBD? more can in as sounds Recorlev also we that March. just product Or given particular? be hopefully, to that's planning you're on for guidance last for Or most more a

John Shannon

taking a of I talked got let the It's days. me a investors forward the what got of And we not -- key we that as at long lot and on short really but in going understand remarks, into truly report shareholders, our a also question, lot of answer. business in a we're all we we're that great -- the account, of And communicate, we've my on. term. will and advice what last so need term We've only for XX can look people lot we said creating should to value to that metrics are we

will measures, I you will to So give but be there going you tell indifferent. I'm more not exact

Operator

the Partners. will from of line be next with question Our Roanna Leerink Ruiz

Unknown Analyst

Curious landing how ask could in whether I trials? outlook you Mick on real titrate stable dose is on to doses sense guess, patent dose look forward the at physicians the for patients reps also then it's any And is where on relative expansion long around from to in taking on what clinical to Recorlev. you world? new and continue Roanna. first here? you And is the sales force going This comment Maybe add to the

John Shannon

with and we've are last on clinicians that at going low the clear We're starting Let because start slow. one. not and doses, really the me been

to take are I long definitely finding to at So that level. up dosing. really don't We're their -- patients. get know we're physicians in strong getting will treating it lower ever really, how results some time on. because stay is going bringing patients But of we're again, in and coming for at to of titrated up. new it's And they're the being doses low low reason period again, the

what as the long where number other -- our at of part rates say, the -- some it's time. number going to that's -- drive as starts, that we expansion. So in do period for increase of XXX% was that and keep new What of

You know a had we made what, got that in we what's as X looking the months I meet order foresight And great at and expansions in X think market the we're to demand. last over on going it.

I think we're in a good spot right now.

So tell -- good for you more our if things that and really exceed levels drive. expansion growth of even on Recorlev, is we but which it's that what would can that expectations, terms more driving accelerate I us -- in product at this place and invest continue getting people to of a the to

Unknown Analyst

That's of it. market to of saw this Got I as year the think you XX% back-to-school then mentioned differences for of And you October. the helpful. in prior any terms Gvoke, dynamics relative years?

quarters whether on what net curious from is gross into could your grow here continue and for outlook share coming in to I'm you So Gvoke the XXXX? to

John Shannon

Because And growth, the almost to other I gaining driving out think we're market -- I moved, I things work, back share QX to that as ones with share. the share every before, think and way becoming growth. was there's QX, said it's we're identical the way the there again.

-- other vaccine the the is not and not growing The growing. kits share,

now. So point that's right just us this at

we that all do that? we're how And of to again, do growth. as, of that see continue course, I capturing So

quarter, pick like we have every been continue up past. to share in we'll So the

Steven Pieper

to net, Yes. I think, question, And Nick. your then was other gross

where to versus discounting. We a continue our access always months. last maintain nets It's trade-off kind over they've been XX to of gross to the of XX

make try to ensure products. pretty but also to have we're that strategic price about And those our we so patients decisions to access protect

just significant So that's of ahead. looking say that to our I and would don't changes gross a saying anticipate long-winded way we

Operator

our Piper will line question Sandler. be the from Amsellem of And Instructions] [Operator with next David

David Amsellem

of longer late, And you're sorry you the how thinking landscape. Keveyis competitive addressed questions. you I about about had term, two just just joined trajectory given One, these talk can so if the

So one, that's that about high the number of your sustainability level, just thoughts product.

sales course, two, of a number such of that other in on products seen acceleration as the are, space. lot a relacorilant. development Cushing just We've in then question And there big-picture and are

You question Recorlev guess, of development, longer more in have an potentially is But term? other for that's concerned here modalities in downstream. asset you the the about way further are with Kinetics noise I how creating

John Shannon

Yes.

we've come Keveyis we've last about new quarters patients, for a slightly the and is do find me you've I at you the keep brand? And you now being in we patients patients to this it's Keveyis. lot think you at is And continue to that then X the And have keep what's And to least and when way it's the quarters, Let cases, -- can patients. we this competition and confidence measure on saying reimbursed started continue back? we're last about what said get them got been we're the So and the at X pharmacy level patients look some growing answer of can how the impacts. of that go and generic first. back, and can in durability patients generic come

some back. our So coming on again base people and bringing we're by patient news maintaining

So we're price, which quarter. this maintaining the we at the pressure on saw getting that numbers some level, in

And that's the payers. the reimbursement pricing just down pharmacy a result on -- of pressures that level to by

-- not patients, So deeply but why it's that the support around by the bit only pressure. the that's and think, are it, again, we're out patients. of the be we think and come winning health so fight we services more continue seeing think this is providers. people to of the can We it it, that, of durable. all valued now and now, And can Keveyis that's -- care There little value more and -- But And a durable. generics right I durable. why be know. we behalf you don't is I we're tell brand right being come on If that after are

brand. in Recorlev, good recognizing respect me is of I that drive a Recorlev refer our you on space areas really the of the is things inhibiting endgame opinion, tailwinds. like managing resistant to mean of think kind all the in comorbidities this culprit the can What's in at one good. And synthesis as is, really these Recorlev you diabetes, here patients. help inhibit cortisol, are activity obesity, in cortisol of our and all level the and really to will going of Cushing's. it cortisol for and with Cushing's, in hypercortisolemia that's resistant I best the heard that as

from it. spot awareness it us. it's that's Happy have testing, think I and a to to So -- benefit lot we more for it a We're all good. because brings good

Operator

no further to closing line, I for call John With on questions the hand now will the remarks. Shannon back

John Shannon

you. closing, revenue, fronts, record XXXX. setting in entire another on team strong the is well Thank a up in In us very resulting for of executing Xeris all finish quarter

to addition our and on are outstanding advancing also significantly programs. commercial as XP-XXXX, product, technology all our In partner lead we pipeline success, our executing planned

to multiple the are positioned a We create being both we I'm in with with fast-growing excited for long near to this products well shareholder promising a are and increasingly us value company as unique confident significant term. biopharmaceutical be recognized and pipeline. morning. Thanks

Operator

today. to you to XXXX Biopharma Xeris Thank Quarter who everyone the Conference conclude join will Financial Call. This Results is us able Third

now may disconnect You your lines.

Xeris Biopharma (XERS) 8 Nov 242024 Q3 Earnings call transcript